During the past few decades there has been a significantly increasing trend in germ cell tumours all over the world, particularly in countries with Caucasian populations. The changes in incidence have occurred so fast that only environmental factors can explain this development. This review focuses on the hypothesis that testicular germ cell cancer, which originates from germ cell neoplasia in situ, is of foetal origin and associated with other male reproductive problems through a testicular dysgenesis syndrome, also including foetal origin of impaired spermatogenesis, hypospadias and cryptorchidism. There is little doubt that environmental factors associated with modern lifestyles have - in a broad sense - had an adverse influence on male reproductive health. The hypothesis that exposure to endocrine-disrupting chemicals plays a fundamental role in this trend is plausible. This is based on evidence from animal studies that demonstrate adverse reproductive effects caused by a number of endocrine-disrupting chemicals to which humans are exposed as part of our modern lifestyle.

Keywords:
Testicular cancer, Testicular dysgenesis syndrome, Endocrine disrupters, Reproduction, Hypospadias, Cryptorchidism
1.
Clemmesen J: A doubling of morbidity from testis carcinoma in Copenhagen, 1943-1962. Acta Pathol Microbiol Scand 1968;72:348-349.
2.
Clemmesen J: Testis cancer incidence - suggestion of a world pattern. Int J Androl 1981;4(suppl 4):111-122.
3.
Znaor A, Lortet-Tieulent J, Jemal A, Bray F: International variations and trends in testicular cancer incidence and mortality. Eur Urol 2014;65:1095-1106.
4.
Le Cornet C, Lortet-Tieulent J, Forman D, Beranger R, Flechon A, Fervers B, Schuz J, Bray F: Testicular cancer incidence to rise by 25% by 2025 in Europe? Model-based predictions in 40 countries using population-based registry data. Eur J Cancer 2014;50:831-839.
5.
Bergström R, Adami HO, Möhner M, Zatonski W, Storm H, Ekbom A, Tretli S, Teppo L, Akre O, Hakulinen T: Increase in testicular cancer incidence in six European countries: a birth cohort phenomenon. J Natl Cancer Inst 1996;88:727-733.
6.
Rajpert-De Meyts E: Developmental model for the pathogenesis of testicular carcinoma in situ: genetic and environmental aspects. Hum Reprod Update 2006;12:303-323.
7.
Hemminki K, Li X: Cancer risks in second-generation immigrants to Sweden. Int J Cancer 2002;99:229-237.
8.
Depue RH, Pike MC, Henderson BE: Estrogen exposure during gestation and risk of testicular cancer. J Natl Cancer Inst 1983;71:1151-1155.
9.
Weir HK, Marrett LD, Kreiger N, Darlington GA, Sugar L: Pre-natal and peri-natal exposures and risk of testicular germ-cell cancer. Int J Cancer 2000;87:438-443.
10.
Hardell L, van Bavel B, Lindstrom G, Eriksson M, Carlberg M: In utero exposure to persistent organic pollutants in relation to testicular cancer risk. Int J Androl 2006;29:228-234.
11.
Skakkebæk NE: Possible carcinoma-in-situ of the testis. Lancet 1972;ii:516-517.
12.
Nielsen H, Nielsen M, Skakkebæk NE: The fine structure of possible carcinoma-in-situ in the seminiferous tubules in the testis of four infertile men. Acta Pathol Microbiol Scand A 1974;82:235-248.
13.
Skakkebæk NE, Berthelsen JG, Giwercman A, Müller J: Carcinoma-in-situ of the testis: possible origin from gonocytes and precursor of all types of germ cell tumours except spermatocytoma. Int J Androl 1987;10:19-28.
14.
Sonne SB, Almstrup K, Dalgaard M, Juncker AS, Edsgard D, Ruban L, Harrison NJ, Schwager C, Abdollahi A, Huber PE, Brunak S, Gjerdrum LM, Moore HD, Andrews PW, Skakkebæk NE, Rajpert-De Meyts E, Leffers H: Analysis of gene expression profiles of microdissected cell populations indicates that testicular carcinoma in situ is an arrested gonocyte. Cancer Res 2009;69:5241-5250.
15.
Rørth M, Rajpert-De Meyts E, Andersson L, Dieckmann KP, Fosså SD, Grigor KM, Hendry WF, Herr HW, Looijenga LHJ, Oosterhuis JW, Skakkebæk NE: Carcinoma in situ in the testis. Scand J Urol Nephrol 2000;205:166-186.
16.
Looijenga LH, Stoop H, de Leeuw HP, Gouveia Brazao CA, Gillis AJ, van Roozendaal KE, van Zoelen EJ, Weber RF, Wolffenbuttel KP, van Dekken H, Honecker F, Bokemeyer C, Perlman EJ, Schneider DT, Kononen J, Sauter G, Oosterhuis JW: POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res 2003;63:2244-2250.
17.
van der Zwan YG, Biermann K, Wolffenbuttel KP, Cools M, Looijenga LH: Gonadal maldevelopment as risk factor for germ cell cancer: towards a clinical decision model. Eur Urol 2015;67:692-701.
18.
Berthelsen JG: Andrological aspects of testicular cancer. Int J Androl 1984;7:451-483.
19.
Berthelsen JG, Skakkebæk NE: Gonadal function in men with testis cancer. Fertil Steril 1983;39:68-75.
20.
Petersen PM, Skakkebæk NE, Vistisen K, Rørth M, Giwercman A: Semen quality and reproductive hormones before orchiectomy in men with testicular cancer. J Clin Oncol 1999;17:941-947.
21.
Dieckmann KP, Linke J, Pichlmeier U, Kulejewski M, Loy V: Spermatogenesis in the contralateral testis of patients with testicular germ cell cancer: histological evaluation of testicular biopsies and a comparison with healthy males. BJU Int 2007;99:1079-1085.
22.
Møller H, Skakkebæk NE: Risk of testicular cancer in subfertile men: case-control study. BMJ 1999;318:559-562.
23.
Morrison AS: Cryptorchidism, hernia, and cancer of the testis. J Natl Cancer Inst 1976;56:731-733.
24.
Giwercman A, Grindsted J, Hansen B, Jensen OM, Skakkebæk NE: Testicular cancer risk in boys with maldescended testis: a cohort study. J Urol 1987;138:1214-1216.
25.
Akre O, Richiardi L: Does a testicular dysgenesis syndrome exist? Hum Reprod 2009;24:2053-2060.
26.
Trabert B, Zugna D, Richiardi L, McGlynn KA, Akre O: Congenital malformations and testicular germ cell tumors. Int J Cancer 2013;133:1900-1904.
27.
Schnack TH, Poulsen G, Myrup C, Wohlfahrt J, Melbye M: Familial coaggregation of cryptorchidism, hypospadias, and testicular germ cell cancer: a nationwide cohort study. J Natl Cancer Inst 2010;102:187-192.
28.
Scully RE: Neoplasia associated with anomalous sexual development and abnormal sex chromosomes. Pediatr Adolesc Endocrinol 1981;8:203-217.
29.
Isidor B, Capito C, Paris F, Baron S, Corradini N, Cabaret B, Leclair MD, Giraud M, Martin-Coignard D, David A, Sultan C, Le Caignec C: Familial frameshift SRY mutation inherited from a mosaic father with testicular dysgenesis syndrome. J Clin Endocrinol Metab 2009;94:3467-3471.
30.
Lottrup G, Jørgensen A, Nielsen JE, Jørgensen N, Duno M, Vinggaard AM, Skakkebæk NE, Rajpert-De Meyts E: Identification of a novel androgen receptor mutation in a family with multiple components compatible with the testicular dysgenesis syndrome. J Clin Endocrinol Metab 2013;98:2223-2229.
31.
Litchfield K, Shipley J, Turnbull C: Common variants identified in genome-wide association studies of testicular germ cell tumour: an update, biological insights and clinical application. Andrology 2015;3:34-46.
32.
Hemminki K, Li X: Familial risk in testicular cancer as a clue to a heritable and environmental aetiology. Br J Cancer 2004;90:1765-1770.
33.
Swerdlow AJ, De Stavola BL, Swanwick MA, Maconochie NE: Risks of breast and testicular cancers in young adult twins in England and Wales: evidence on prenatal and genetic aetiology. Lancet 1997;350:1723-1728.
34.
Kang JL, Rajpert-De Meyts E, Giwercman A, Skakkebæk NE: The association of testicular carcinoma in situ with intratubular microcalcifications. J Urol Pathol 1994;2:235-242.
35.
Høi-Hansen CE, Holm M, Rajpert-De Meyts E, Skakkebæk NE: Histological evidence of testicular dysgenesis in contralateral biopsies from 218 patients with testicular germ cell cancer. J Pathol 2003;200:370-374.
36.
Skakkebæk NE, Rajpert-De Meyts E, Main KM: Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Hum Reprod 2001;16:972-978.
37.
Skakkebæk NE, Rajpert-De Meyts E, Buck Louis GM, Toppari J, Andersson AM, Eisenberg ML, Jensen TK, Jorgensen N, Swan SH, Sapra KJ, Ziebe S, Priskorn L, Juul A: Male reproductive disorders and fertility trends: influences of environment and genetic susceptibility. Physiol Rev 2016;96:55-97.
38.
Shahid M, Dhillon VS, Khalil HS, Haque S, Batra S, Husain SA, Looijenga LH: A SRY-HMG box frame shift mutation inherited from a mosaic father with a mild form of testicular dysgenesis syndrome in Turner syndrome patient. BMC Med Genet 2010;11:131.
39.
Skakkebæk NE, Høi-Hansen CE, Holm M, Jørgensen N, Rajpert-De Meyts E: Association between testicular dysgenesis syndrome (TDS) and testicular neoplasia: evidence from 20 adult patients with signs of maldevelopment of the testis. APMIS 2003;111:1-9; discussion 9-11.
40.
Rajpert-De Meyts E, Skakkebæk NE: Pathogenesis of testicular carcinoma in situ and germ cell cancer: still more questions than answers. Int J Androl 2011;34:e2-e6.
41.
Kelce WR, Lambright CR, Gray LE Jr, Roberts KP: Vinclozolin and p,p'-DDE alter androgen-dependent gene expression: in vivo confirmation of an androgen receptor-mediated mechanism. Toxicol Appl Pharmacol 1997;142:192-200.
42.
Kelce WR, Stone CR, Laws SC, Gray LE Jr, Kemppainen JA, Wilson EM: Persistent DDT metabolite, p,p'-DDE is a potent androgen receptor antagonist. Nature 1995;375:581-585.
43.
Gray LE Jr, Ostby JS, Kelce WR: Developmental effects of an environmental antiandrogen: the fungicide vinclozolin alters sex differentiation of the male rat. Toxicol Appl Pharmacol 1994;129:46-52.
44.
Gray LE Jr, Ostby J, Furr J, Price M, Veeramachaneni DN, Parks L: Perinatal exposure to the phthalates DEHP, BBP, and DINP, but not DEP, DMP, or DOTP, alters sexual differentiation of the male rat. Toxicol Sci 2000;58:350-365.
45.
Fisher JS, Macpherson S, Marchetti N, Sharpe RM: Human ‘testicular dysgenesis syndrome': a possible model using in-utero exposure of the rat to dibutyl phthalate. Hum Reprod 2003;18:1383-1394.
46.
Welsh M, Saunders PT, Fisken M, Scott HM, Hutchison GR, Smith LB, Sharpe RM: Identification in rats of a programming window for reproductive tract masculinization, disruption of which leads to hypospadias and cryptorchidism. J Clin Invest 2008;118:1479-1490.
47.
Sharpe RM, Skakkebæk NE: Are oestrogens involved in falling sperm counts and disorders of the male reproductive tract? Lancet 1993;341:1392-1395.
48.
McLachlan JA, Newbold RR, Burow ME, Li SF: From malformations to molecular mechanisms in the male: three decades of research on endocrine disrupters. APMIS 2001;109:263-272.
49.
Main KM, Rajpert-De Meyts E, Toppari J, Skakkebæk NE: Endocrine disrupters and development of the reproductive system: a paediatric perspective; in Pescovitz OH, Eugster EA (eds): Pediatric Endocrinology: Mechanisms. Philadelphia, Lippincott, Williams & Wilkins, 2004, pp 376-390.
50.
Toppari J, Larsen JC, Christiansen P, Giwercman A, Grandjean P, Guillette LJ Jr, Jégou B, Jensen TK, Jouannet P, Keiding N, Leffers H, McLachlan JA, Meyer O, Müller J, Rajpert- De Meyts E, Scheike T, Sharpe R, Sumpter J, Skakkebæk NE: Male reproductive health and environmental xenoestrogens. Environ Health Perspect 1996;104:741-803.
51.
Christiansen S, Scholze M, Axelstad M, Boberg J, Kortenkamp A, Hass U: Combined exposure to anti-androgens causes markedly increased frequencies of hypospadias in the rat. Int J Androl 2008;31:241-248.
52.
Rider CV, Furr J, Wilson VS, Gray LE Jr: A mixture of seven antiandrogens induces reproductive malformations in rats. Int J Androl 2008;31:249-262.
53.
Schindler BK, Esteban M, Koch HM, Castano A, Koslitz S, Canas A, Casteleyn L, Kolossa-Gehring M, Schwedler G, Schoeters G, Hond ED, Sepai O, Exley K, Bloemen L, Horvat M, Knudsen LE, Joas A, Joas R, Biot P, Aerts D, Lopez A, Huetos O, Katsonouri A, Maurer-Chronakis K, Kasparova L, Vrbik K, Rudnai P, Naray M, Guignard C, Fischer ME, Ligocka D, Janasik B, Reis MF, Namorado S, Pop C, Dumitrascu I, Halzlova K, Fabianova E, Mazej D, Tratnik JS, Berglund M, Jonsson B, Lehmann A, Crettaz P, Frederiksen H, Nielsen F, McGrath H, Nesbitt I, De Cremer K, Vanermen G, Koppen G, Wilhelm M, Becker K, Angerer J: The European COPHES/DEMOCOPHES project: towards transnational comparability and reliability of human biomonitoring results. Int J Hyg Environ Health 2014;217:653-661.
54.
Vandenberg LN, Chahoud I, Heindel JJ, Padmanabhan V, Paumgartten FJ, Schoenfelder G: Urinary, circulating, and tissue biomonitoring studies indicate widespread exposure to bisphenol A. Environ Health Perspect 2010;118:1055-1070.
55.
Frederiksen H, Jensen TK, Jørgensen N, Boye KH, Husby S, Skakkebæk NE, Main KM, Juul A, Andersson AM: Human urinary excretion of non-persistent environmental chemicals: an overview of Danish data collected 2006-2012. Reproduction 2014;147:555-565.
56.
Krysiak-Baltyn K, Toppari J, Skakkebæk NE, Jensen TS, Virtanen HE, Schramm KW, Shen H, Vartiainen T, Kiviranta H, Taboureau O, Brunak S, Main KM: Country-specific chemical signatures of persistent environmental compounds in breast milk. Int J Androl 2010;33:270-278.
57.
Zietz BP, Hoopmann M, Funcke M, Huppmann R, Suchenwirth R, Gierden E: Long-term biomonitoring of polychlorinated biphenyls and organochlorine pesticides in human milk from mothers living in northern Germany. Int J Hyg Environ Health 2008;211:624-638.
58.
Skakkebæk NE, Rajpert-De Meyts E, Jørgensen N, Main KM, Leffers H, Andersson AM, Juul A, Jensen TK, Toppari J: Testicular cancer trends as ‘whistle blowers' of testicular developmental problems in populations. Int J Androl 2007;30:198-205.
59.
Virtanen HE, Bjerknes R, Cortes D, Jørgensen N, Rajpert-De Meyts E, Thorsson AV, Thorup J, Main KM: Cryptorchidism: classification, prevalence and long-term consequences. Acta Paediatr 2007;96:611-616.
60.
Chul KS, Kyoung KS, Pyo HY: Trends in the incidence of cryptorchidism and hypospadias of registry-based data in Korea: a comparison between industrialized areas of petrochemical estates and a non-industrialized area. Asian J Androl 2011;13:715-718.
61.
Paulozzi LJ: International trends in rates of hypospadias and cryptorchidism. Environ Health Perspect 1999;107:297-302.
62.
Pierik FH, Burdorf A, de Muinck Keizer-Schrama SM, Wolffenbuttel KP, Nijman JM, Juttmann RE, Weber RF: The cryptorchidism prevalence among infants in the general population of Rotterdam, the Netherlands. Int J Androl 2005;28:248-252.
63.
Travison TG, Araujo AB, O'Donnell AB, Kupelian V, McKinlay JB: A population-level decline in serum testosterone levels in American men. J Clin Endocrinol Metab 2007;92:196-202.
64.
Andersson AM, Jensen TK, Juul A, Petersen JH, Jørgensen T, Skakkebæk NE: Secular decline in male testosterone and sex hormone binding globulin serum levels in Danish population surveys. J Clin Endocrinol Metab 2007;92:4696-4705.
65.
Perheentupa A, Makinen J, Laatikainen T, Vierula M, Skakkebæk NE, Andersson AM, Toppari J: A cohort effect on serum testosterone levels in Finnish men. Eur J Endocrinol 2013;168:227-233.
66.
Jensen TK, Swan S, Jørgensen N, Toppari J, Redmon B, Punab M, Drobnis EZ, Haugen TB, Zilaitiene B, Sparks AE, Irvine DS, Wang C, Jouannet P, Brazil C, Paasch U, Salzbrunn A, Skakkebæk NE, Andersson AM: Alcohol and male reproductive health: a cross-sectional study of 8344 healthy men from Europe and the USA. Hum Reprod 2014;29:1801-1809.
67.
Ravnborg TL, Jensen TK, Andersson AM, Toppari J, Skakkebæk NE, Jørgensen N: Prenatal and adult exposures to smoking are associated with adverse effects on reproductive hormones, semen quality, final height and body mass index. Hum Reprod 2011;26:1000-1011.
68.
Juul A, Almstrup K, Andersson AM, Jensen TK, Jørgensen N, Main KM, Rajpert-De Meyts E, Toppari J, Skakkebæk NE: Possible fetal determinants of male infertility. Nat Rev Endocrinol 2014;10:553-562.
69.
Krause M, Klit A, Blomberg Jensen M, Søeborg T, Frederiksen H, Schlumpf M, Lichtensteiger W, Skakkebæk NE, Drzewiecki KT: Sunscreens: are they beneficial for health? An overview of endocrine disrupting properties of UV-filters. Int J Androl 2012;35:424-436.
70.
WHO, UNEP: State of the science of endocrine disrupting chemicals 2012: an assessment of the state of the science of endocrine disruptors prepared by a group of experts for the United Nations Environment Programme and World Health Organization. Geneva, WHO, 2013.
71.
Hauser R, Skakkebæk NE, Hass U, Toppari J, Juul A, Andersson AM, Kortenkamp A, Heindel JJ, Trasande L: Male reproductive disorders, diseases, and costs of exposure to endocrine-disrupting chemicals in the European Union. J Clin Endocrinol Metab 2015;100:1267-1277.
72.
Trasande L, Zoeller RT, Hass U, Kortenkamp A, Grandjean P, Myers JP, DiGangi J, Bellanger M, Hauser R, Legler J, Skakkebæk NE, Heindel JJ: Estimating burden and disease costs of exposure to endocrine-disrupting chemicals in the European Union. J Clin Endocrinol Metab 2015;100:1245-1255.
73.
Fang J, Nyberg E, Bignert A, Bergman A: Temporal trends of polychlorinated dibenzo-p-dioxins and dibenzofurans and dioxin-like polychlorinated biphenyls in mothers' milk from Sweden, 1972-2011. Environ Int 2013;60:224-231.
74.
Bergman A, Heindel JJ, Kasten T, Kidd KA, Jobling S, Neira M, Zoeller RT, Becher G, Bjerregaard P, Bornman R, Brandt I, Kortenkamp A, Muir D, Drisse MN, Ochieng R, Skakkebæk NE, Bylehn AS, Iguchi T, Toppari J, Woodruff TJ: The impact of endocrine disruption: a consensus statement on the state of the science. Environ Health Perspect 2013;121:A104-A106.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.